DiaSorin pursues India Dx market through Trivitron partnership

Italian diagnostics company DiaSorin Group will partner with Indian medical technology giant Trivitron Healthcare in a bid to grab a piece of India's surging in vitro diagnostics market.

Neither side is disclosing financial terms. But the arrangement calls for the formation of a limited liability company, dubbed DiaSorin Trivitron Healthcare Private Limited, which will sell in vitro diagnostics products for both companies and be based out of Chennai. DiaSorin will hold a 51% stake and Trivitron will hold onto 49%.

Trivitron itself is drawing attention from all kinds of places. Medtronic is reportedly negotiating for a possible stake in the company, according to reports, with Trivitron rumored to be moving into device manufacturing.

Estimates place the Indian IVD market at €400 million (more than $494 million), with 15% annual growth. The partnership makes sense, too. Device and diagnostics companies have long been told that they can make better progress in India--the world's second fastest growing IVD market after China, according to estimates--by joining forces with a local partner.

Trivitron is among the three largest Indian medical device companies and has a large presence in in vitro diagnostics based on other multinational-company partnerships. DiaSorin sells in vitro diagnostics equipment and tests, according to Reuters. And the combined partnership hopes to take the lead in the Indian IVD market within three years.

- here's the partnership announcement
- read the Reuters story

Suggested Articles

BD will begin working with Babson Diagnostics to help bring its lab-quality device for collecting blood from capillaries into retail pharmacies.

The former CEO of the molecular testing company Foundation Medicine, Troy Cox, has been named chairman of the Swiss big data firm Sophia Genetics.

Researchers at MIT used a machine-learning algorithm to uncover the potent antibiotic properties hiding within an old small-molecule candidate.